BACKGROUND: Hemodynamic and neurohumoral function can affect the efficacy of diuretic therapy in congestive heart failure. Arginine vasopressin increases water reabsorption through the V(2) receptor in the collecting duct, whereas B-type natriuretic peptide (BNP) decreases sodium reabsorption in the collecting duct. We hypothesized that combining BNP to the V(2)-receptor antagonist tolvaptan (TLV) would enhance renal excretory function by augmenting sodium excretion together with aquaresis without adversely affecting renal hemodynamics in experimental congestive heart failure. METHODS AND RESULTS: Congestive heart failure was induced in 3 groups (n=6 per group) of dogs by tachypacing. A acute experiment was done after 10 days. After baseline measurements, study groups received a 0.1 mg/kg IV bolus of TLV alone (TLV), TLV in combination with BNP (TLV+BNP; 50 ng/[kg . min]), or BNP alone (BNP). Mean arterial pressure increased with TLV, remained unchanged with TLV+BNP, and decreased with BNP (+5+/-1mm Hg versus -1+/-1 mm Hg versus -15+/-1 mm Hg; P<0.05). Renal blood flow and glomerular filtration rate were preserved with all regimens. Urine flow increased in all 3 groups but significantly more so with TLV+BNP (TLV: +0.4+/-0.1 mL/min versus TLV+BNP: +2.4+/-0.5 mL/min versus BNP: +0.8+/-0.3 mL/min; P<0.05). Only TLV+BNP and BNP were natriuretic (P<0.05), whereas only TLV and TLV+BNP increased electrolyte-free water excretion (P<0.05). Compared with TLV alone, TLV+BNP prevented an increase in aldosterone (P<0.05). CONCLUSIONS: Coadministration of TLV and BNP in experimental HF resulted in a beneficial profile of renal, neurohumoral, and hemodynamic actions, specifically potent diuresis with natriuresis, neutral effect on mean arterial pressure, and lack of aldosterone activation.
BACKGROUND: Hemodynamic and neurohumoral function can affect the efficacy of diuretic therapy in congestive heart failure. Arginine vasopressin increases water reabsorption through the V(2) receptor in the collecting duct, whereas B-type natriuretic peptide (BNP) decreases sodium reabsorption in the collecting duct. We hypothesized that combining BNP to the V(2)-receptor antagonist tolvaptan (TLV) would enhance renal excretory function by augmenting sodium excretion together with aquaresis without adversely affecting renal hemodynamics in experimental congestive heart failure. METHODS AND RESULTS:Congestive heart failure was induced in 3 groups (n=6 per group) of dogs by tachypacing. A acute experiment was done after 10 days. After baseline measurements, study groups received a 0.1 mg/kg IV bolus of TLV alone (TLV), TLV in combination with BNP (TLV+BNP; 50 ng/[kg . min]), or BNP alone (BNP). Mean arterial pressure increased with TLV, remained unchanged with TLV+BNP, and decreased with BNP (+5+/-1mm Hg versus -1+/-1 mm Hg versus -15+/-1 mm Hg; P<0.05). Renal blood flow and glomerular filtration rate were preserved with all regimens. Urine flow increased in all 3 groups but significantly more so with TLV+BNP (TLV: +0.4+/-0.1 mL/min versus TLV+BNP: +2.4+/-0.5 mL/min versus BNP: +0.8+/-0.3 mL/min; P<0.05). Only TLV+BNP and BNP were natriuretic (P<0.05), whereas only TLV and TLV+BNP increased electrolyte-free water excretion (P<0.05). Compared with TLV alone, TLV+BNP prevented an increase in aldosterone (P<0.05). CONCLUSIONS: Coadministration of TLV and BNP in experimental HF resulted in a beneficial profile of renal, neurohumoral, and hemodynamic actions, specifically potent diuresis with natriuresis, neutral effect on mean arterial pressure, and lack of aldosterone activation.
Authors: Guido Boerrigter; Lisa C Costello-Boerrigter; Gail J Harty; Harald Lapp; John C Burnett Journal: Am J Physiol Regul Integr Comp Physiol Date: 2006-10-26 Impact factor: 3.619
Authors: Marvin A Konstam; Mihai Gheorghiade; John C Burnett; Liliana Grinfeld; Aldo P Maggioni; Karl Swedberg; James E Udelson; Faiez Zannad; Thomas Cook; John Ouyang; Christopher Zimmer; Cesare Orlandi Journal: JAMA Date: 2007-03-25 Impact factor: 56.272
Authors: Mihai Gheorghiade; Marvin A Konstam; John C Burnett; Liliana Grinfeld; Aldo P Maggioni; Karl Swedberg; James E Udelson; Faiez Zannad; Thomas Cook; John Ouyang; Christopher Zimmer; Cesare Orlandi Journal: JAMA Date: 2007-03-25 Impact factor: 56.272
Authors: Mihai Gheorghiade; William T Abraham; Nancy M Albert; Wendy Gattis Stough; Barry H Greenberg; Christopher M O'Connor; Lilin She; Clyde W Yancy; James Young; Gregg C Fonarow Journal: Eur Heart J Date: 2007-02-19 Impact factor: 29.983
Authors: Jens Klokkers; Patrik Langehanenberg; Björn Kemper; Sebastian Kosmeier; Gert von Bally; Christoph Riethmüller; Frank Wunder; Aleksandra Sindic; Hermann Pavenstädt; Eberhard Schlatter; Bayram Edemir Journal: Am J Physiol Renal Physiol Date: 2009-07-01
Authors: Hans L Hillege; Dorothea Nitsch; Marc A Pfeffer; Karl Swedberg; John J V McMurray; Salim Yusuf; Christopher B Granger; Eric L Michelson; Jan Ostergren; Jan Hein Cornel; Dick de Zeeuw; Stuart Pocock; Dirk J van Veldhuisen Journal: Circulation Date: 2006-02-07 Impact factor: 29.690
Authors: James E Udelson; Cesare Orlandi; John Ouyang; Holly Krasa; Christopher A Zimmer; Geir Frivold; W Herbert Haught; Sheiba Meymandi; Cezar Macarie; Dimitar Raef; Patricia Wedge; Marvin A Konstam; Mihai Gheorghiade Journal: J Am Coll Cardiol Date: 2008-11-04 Impact factor: 24.094
Authors: Joan Li; Usukhbayar Ariunbold; Norseha Suhaimi; Nana Sunn; Jinjin Guo; Jill A McMahon; Andrew P McMahon; Melissa Little Journal: J Am Soc Nephrol Date: 2014-06-05 Impact factor: 10.121
Authors: Tomoko Ichiki; Guido Boerrigter; Brenda K Huntley; S Jeson Sangaralingham; Paul M McKie; Gail J Harty; Gerald E Harders; John C Burnett Journal: Am J Physiol Regul Integr Comp Physiol Date: 2012-11-14 Impact factor: 3.619